Search Results

You are looking at 11 - 20 of 493 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Where Your Data Is Going and Where It's Been

Jane M. Quigley

Albumin-Bound Paclitaxel Where Will Your Data Go Next? Collecting data is time-consuming and expensive. Electronic transactions, including electronic medical records and the unification of many billing procedures, have transformed the rate at

Full access

Undetectable Tumor Cell-Free DNA in a Patient With Metastatic Breast Cancer With Complete Response and Long-Term Remission

Natasha Hunter, Sarah Croessmann, Karen Cravero, Daniel Shinn, Paula J. Hurley, and Ben Ho Park

with estrogen receptor (ER)/progesterone receptor (PR)–negative, HER2-positive metastatic breast cancer who received trastuzumab and nab-paclitaxel in 2008 and experienced a complete remission (CR). Remarkably, she continues to have no evidence of

Full access

Strategies for the Management of Early-Stage Breast Cancer in Older Women

Lee S. Schwartzberg and Sarah L. Blair

: AC, anthracycline/cyclophosphamide; CMF, cyclophosphamide/methotrexate/fluorouracil; doc, docetaxel; G-CSF, granulocyte colony-stimulating factor; pts, patients; T, paclitaxel; TC, docetaxel/cyclophosphamide; TCH, docetaxel

Full access

First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort

Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group

that demonstrated a survival improvement compared with gemcitabine monotherapy was gemcitabine in combination with nab-paclitaxel, with a median OS of 8.5 months versus 6.7 months for gemcitabine alone. 5 , 14 Currently FOLFIRINOX and gemcitabine with

Full access

Counterpoint: Intraperitoneal Chemotherapy: An Investigational Treatment in Ovarian Cancer

Robert F. Ozols

Ozols RF . Intraperitoneal therapy in ovarian cancer: Time's up . J Clin Oncol 1991 ; 9 : 197 – 199 . 4 Markman M Bundy BN Alberts DS . Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high

Full access

A Novel Approach Using Sorafenib in Alpha Fetoprotein–Producing Hepatoid Adenocarcinoma of the Lung

Tatjana Gavrancic and Yeun-Hee Anna Park

/mL). The patient was diagnosed with stage IV HAL and started on palliative chemotherapy with carboplatin/paclitaxel and sorafenib (400 mg orally twice daily), followed by palliative radiation to the vertebrae for a total dose of 30 Gy. After 2 cycles of

Full access

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

tested these recommended regimens. 171 – 175 , 177 – 196 The most commonly-used regimen, paclitaxel 175/carboplatin, has been considered the standard postoperative chemotherapy for ovarian cancer for many years, so there are many studies in which it has

Full access

Multidisciplinary Management of Pancreatic Cancer

Margaret A. Tempero

become more effective with the use of newer, presumably more active regimens, in particular FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel. Based on their benefit in the metastatic setting, these

Full access

Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations

Cesar A. Santa-Maria, Maureen O’Donnell, Raquel Nunes, Jean L. Wright, and Vered Stearns

weekly paclitaxel, and all patients received dose-dense (every 2 weeks) doxorubicin and cyclophosphamide (AC). A number of studies have been reported since then, with some, but not all, showing improvements in pCR in the ICI-containing arms ( Table 1 ). 3

Full access

Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options

Presented by: Margaret A. Tempero

neuropathy.” Omitting bolus fluorouracil, reducing doses, eliminating drugs that cause excessive toxicity, and using chemotherapy holidays have been found to increase the tolerability of this regimen. Another frequently used regimen, nab-paclitaxel